SCHEMBL9976019

SCHEMBL9976019

O=S(=O)(c1cccc2ccccc12)N1CCN(Cc2ccc3cccnc3c2O)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.56
SMN1; SMN2 Q16637 5/20 0.54
KDM4E B2RXH2 5/20 0.54
L3MBTL1 Q9Y468 4/20 0.54
HTT P42858 4/20 0.54
MAPK1 P28482 3/20 0.54
LMNA P02545 3/20 0.54
RAB9A P51151 3/20 0.54
MITF O75030 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
NPC1 O15118 2/20 0.54
GAA P10253 2/20 0.52
MAPT P10636 2/20 0.52
PKM P14618 1/20 0.52
FABP1 P07148 4/20 0.51
ALDH1A1 P00352 2/20 0.50
HSD11B1 P28845 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TP53 P04637 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9976060 0.88 KMT2A (0.51) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL9975981 0.85 BCHE (0.60) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL9976024 0.84 L3MBTL1 (0.57) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL9976020 0.82 BCHE (0.57) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL9975988 0.82 KDM4E (0.60) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL9975989 0.82 KDM4E (0.57) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL26241625 0.81 BCHE (0.74) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL9975985 0.80 HTT (0.63) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL9975982 0.80 KDM4E (0.58) BCHESMN1; SMN2KDM4EL3MBTL1HTT
SCHEMBL9975984 0.80 HTT (0.58) BCHESMN1; SMN2KDM4EL3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
WO-2012087889-A2 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-28 WO disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157465-A1 DNA METHYLATION INHIBITORS MECP2, DNMT1, DNMT3B BCHE 1342/4885SMN1; SMN2 3853/4885KDM4E 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.